NCT06856928Not yet recruiting
Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.
Source: ClinicalTrials.gov · Last updated 4 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to explore how anti-obesity medications (AOMs) like semaglutide and tirzepatide affect appetite and energy intake. Researchers will examine two groups: one just starting AOMs and another that has already achieved significant weight loss and maintained it. By conducting meal challenges at different stages of medication use, the study will assess feasibility of the methods and gather preliminary data to design a larger, future study.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 16 (estimated)
- First submitted
- 13 Feb 2025
- Start date
- Mar 2025
- Primary completion date
- Dec 2026
- Lead sponsor
- University of Colorado, Denver
- Diseases
- Obesity
- NCT number
- NCT06856928
What you commit to
- Study type: Observational
- Planned participants: 16
- From Mar 2025 to the primary completion date, Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous surgical treatment or device-based therapy for obesity
Other illness
- Diagnosed with type 1 or 2 diabetes
- Uncontrolled hypertension or hypo/hyperthyroidism
- Acute or chronic hepatitis
Other
- Smoker
- Chronic or acute pancreatitis
- Clinically significant gastric emptying abnormality
- Cardiovascular event 3 months within screening
- Inability to tolerate beef, eggs, and cheese
- Women who are pregnant
- Women who are nursing
Who the study is looking for
- Adult males and females with a BMI of 30-45 kg/m2 (early group), or a BMI of 30-45 kg/m2 prior to weight loss achieved through medication (late group)
- Age, 25-60 years old
- Passing medical and physical screening, and analysis of blood and urine screening samples
- Anticipated to start or are already prescribed AOMs (semaglutide or tirzepatide)
- 6-months weight stable (early group) or 3 months weight stable at current weight (late group)
- Women of reproductive age must be using an effective form of contraception
Age in the registry: 25 years to 60 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.